Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
about
Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in HCV-Negative Subjects.Clinical trials: Treatment of HCV-infected patients with advanced kidney disease.HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs).Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Hepatitis C virus infection in chronic kidney disease: paradigm shift in management.Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.Glecaprevir/pibrentasvir for hepatitis CEra of direct acting anti-viral agents for the treatment of hepatitis CResistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionPooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsHepatitis C and renal transplantation in era of new antiviral agents
P2860
Q47396298-208C5F4D-BD0A-41C3-97CA-63FCB4BA82B3Q47562694-150FE100-3F1F-4643-AB0E-A0CA65E0A3CAQ47695767-C5609086-8547-44C9-A312-B34B25D2DA48Q50145685-6D825098-ABA0-478F-8676-2E69D356A92CQ50318635-76D26514-8C44-4039-8B32-EC453C8D3FA0Q54223871-88028B7F-2879-4A76-A0B5-7CB29BEB9954Q55501318-10631B01-DC13-4F7A-A736-35616C061BE9Q55508515-87F76148-A293-4A5D-9EA8-FB2E682A45C9Q58588862-2F1F5A77-5A18-464E-8A7E-2B58B5810B37Q58603882-3350F029-925B-42B9-85F8-FBE90C3FCFB1Q58697287-620A31E4-1CE1-45ED-83C2-18CDE71547B8Q58701132-6D4138A3-91F3-4049-818A-DA540E841DD6Q58792851-98B5E6D6-EA20-4B5A-8CFE-F64270FC52A9
P2860
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
@en
type
label
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
@en
prefLabel
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
@en
P2093
P356
P1476
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
@en
P2093
Ashley Brown
Christine Collins
Christophe Moreno
David Pugatch
David R Nelson
Edward Gane
Eric Lawitz
Eric M Yoshida
Federico J Mensa
Georgios Papatheodoridis
P304
P356
10.1056/NEJMOA1704053
P407
P577
2017-10-01T00:00:00Z